Sage Journals: Discover world-class research

Abstract

Background:

Comorbid chronic obstructive pulmonary disease is found in approximately one-third of patients with heart failure. Survival in patients with chronic obstructive pulmonary disease generally decreases as lung function declines. However, the association between lung function, hospitalization and survival is less clear for patients with heart failure.

Aim:

The purpose of this study was to determine the predictive power of spirometry measures for event-free survival (combined all-cause hospitalization and/or mortality) in patients with heart failure.

Methods:

In this secondary analysis of data from three prospective, longitudinal studies, we selected patients with a confirmed diagnosis of heart failure who completed airflow limitation assessment using spirometry measures (n=137): forced vital capacity, forced expiratory volume/second, and forced expiratory volume/second/forced vital capacity. Cox proportional hazards modeling was used to determine the relationship between spirometry and all-cause hospitalization/mortality with and without adjusting for demographic and clinical covariates over a four-year follow-up period.

Results:

A majority (74%) exhibited some degree of airflow limitation (forced expiratory volume/second<80% predicted value) and 26 (19%) met the spirometric criterion for chronic obstructive pulmonary disease (forced expiratory volume/second/forced vital capacity⩽0.70). Cox proportional hazards regression models compared all-cause hospitalization/mortality between those with and without airflow limitation. Patients with airflow limitation were 2.2 times more likely to be hospitalized or die compared to those without airflow limitations (hazard ratio: 2.20, 95% confidence interval 1.06–4.53, p=0.03).

Conclusion:

Patients with comorbid heart failure and airflow limitation were at more than double the risk for an event. Spirometric measures may be useful to patients with heart failure, as tailored management of airflow limitation may impact event-free survival.

Keywords

Chronic obstructive pulmonary disease heart failure airflow limitation survival

Get full access to this article

View all access options for this article.

References

World Health Organization. NCD mortality and morbidity. World Health Organization, 2017. Geneva, Switzerland.

World Health Organization. Burden of COPD, http://www.who.int/respiratory/copd/burden/en/ (2016, accessed 25 March 2017).

Baker

Wilcox

RG.

Beta-blockers, heart disease and COPD: Current controversies and uncertainties. Thorax 2017; 72: 271–276.

Gong

et al . Pulmonary function and arterial stiffness in chronic heart failure. Biomed Res Int 2016; 2016: 5478394.

Anzueto

Miravitlles

Pathophysiology of dyspnea in COPD. Postgrad Med 2017; 129: 366–374.

Testa

Cacciatore

Bianco

et al . Chronic obstructive pulmonary disease and long-term mortality in elderly subjects with chronic heart failure. Aging Clin Exp Res 2017; 29: 1157–1164.

Benjamin

Wang

Geiss

et al . The impact of repeat hospitalizations on hospitalization rates for selected conditions among adults with and without diabetes, 12 US states, 2011. Prev Chronic Dis 2015; 12: E200.

Cully

Graham

Stanley

et al . Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 2006; 47: 312–319.

Nesbitt

Doctorvaladan

Southard

et al . Correlates of quality of life in rural patients with heart failure. Circ Heart Fail 2014; 7: 882–887.

10.

Heo

Moser

Lennie

et al . A comparison of health-related quality of life between older adults with heart failure and healthy older adults. Heart Lung 2007; 36: 16–24.

11.

Blecker

Paul

Taksler

et al . Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol 2013; 61: 1259–1267.

12.

Yohannes

Alexopoulos

GS.

Depression and anxiety in patients with COPD. Eur Respir Rev 2014; 23: 345–349.

13.

Wang

et al . Daily symptom variability in patients with stable COPD: A narrative review. West J Nurs Res 2018; 40: 1543–1561.

14.

Kupper

Bonhof

Westerhuis

et al . Determinants of dyspnea in chronic heart failure. J Card Fail 2016; 22: 201–209.

15.

Lee

Jhun

Cho

et al . Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity. Int J Chron Obstruct Pulmon Dis 2017; 12: 3301–3310.

16.

Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: https://goldcopd.org (accessed 25 March 2017)

17.

Qaseem

Alguire

Dallas

et al . Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care. Ann Intern Med 2012; 156: 147–149.

18.

Boutou

Shrikrishna

Tanner

et al . Lung function indices for predicting mortality in COPD. Eur Respir J 2013; 42: 616–625.

19.

Mantero

Rogliani

Di Pasquale

et al . Acute exacerbations of COPD: Risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis 2017; 12: 2687–2693.

20.

Plesner

Dalsgaard

Schou

et al . The prognostic significance of lung function in stable heart failure outpatients. Clin Cardiol 2017; 40: 1145–1151.

21.

Menezes

Perez-Padilla

Wehrmeister

et al . FEV1 is a better predictor of mortality than FVC: The PLATINO cohort study. PLoS One 2014; 9: e109732.

22.

Arnaudis

Lairez

Escamilla

et al . Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure. Clin Res Cardiol 2012; 101: 717–726.

23.

Mascarenhas

Lourenco

Lopes

et al . Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008; 155: 521–525.

24.

Lee

Moser

Lennie

et al . Event-free survival in adults with heart failure who engage in self-care management. Heart Lung 2011; 40: 12–20.

25.

Moser

Chung

et al . Predictors of medication adherence using a multidimensional adherence model in patients with heart failure. J Card Fail 2008; 14: 603–614.

26.

Moser

Rayens

et al . Rurality and event-free survival in patients with heart failure. Heart Lung 2010; 39: 512–520.

27.

Human experimentation: Code of ethics of W.M.A. BMJ 1964; 2: 177.

28.

Riegel

Moser

Anker

et al . State of the science: Promoting self-care in persons with heart failure: A scientific statement from the American Heart Association. Circulation 2009; 120: 1141–1163.

29.

Laszlo

Standardisation of lung function testing: Helpful guidance from the ATS/ERS Task Force. Thorax 2006; 61: 744–746.

30.

Evans

Scanlon

PD.

Current practice in pulmonary function testing. Mayo Clin Proc 2003; 78: 758–763; quiz 763.

31.

Breitling

Ravindran

Goldenberg

et al . The pathophysiology of pulmonary hypertension in left heart disease. Am J Physiol Lung Cell Mol Physiol 2015; 309: L924–941.

32.

Guazzi

Gatto

Giusti

et al . Pathophysiology of cardiorenal syndrome in decompensated heart failure: Role of lung-right heart-kidney interaction. Int J Cardiol 2013; 169: 379–384.

33.

Melenovsky

Andersen

Andress

et al . Lung congestion in chronic heart failure: Haemodynamic, clinical, and prognostic implications. Eur J Heart Fail 2015; 17: 1161–1171.

34.

Guder

Rutten

Brenner

et al . The impact of heart failure on the classification of COPD severity. J Card Fail 2012; 18: 637–644.

35.

Moser

Frazier

Worrall-Carter

et al . Symptom variability, not severity, predicts rehospitalization and mortality in patients with heart failure. Eur J Cardiovasc Nurs 2011; 10: 124–129.

36.

Bektas

Franssen

van Empel

et al . Impact of airflow limitation in chronic heart failure. Neth Heart J 2017; 25: 335–342.

37.

Wada

Nakano

Nagao

et al . Detection and prevalence of chronic obstructive pulmonary disease in a cardiovascular clinic: Evaluation using a hand held FEV(1)/FEV(6) meter and questionnaire. Respirology 2010; 15: 1252–1258.

38.

Conrad

Judge

Tran

et al . Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals. Lancet 2018; 391: 572–580.

39.

Johannessen

Omenaas

Bakke

et al . Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: A community study. Thorax 2005; 60: 842–847.

Airflow limitation more than doubles the risk for hospitalization/mortality in patients with heart failure

Abstract

Background:

Aim:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References